A $377 Million SPAC at Trust Value: What Corxel's Obesity Listing Says About Pricing a Pre-Revenue Pill

Amanat's own capitalization slide is the most honest document in the file. It states that the illustrative share price is set to equal the trust's estimated redemption price at closing, which means the rollover, the sponsor, the trust and the new money are all marked at roughly $10 a share. Nobody pays a premium for CX11's Phase 3-ready status.

The consequence is a quiet transfer of control: the new money takes 50.1% of the company at a flat $10.00 a share, while the holders who ran the U.S. Phase 2 keep 33.4%. Public shareholders end up with 12.8% and the sponsor with 3.7%. The redemption assumption is doing all the work in those numbers, because the presentation holds the full $75 million of trust money on the balance sheet on the assumption that nobody redeems.

Redemption is unusually harsh here. Amanat sold 7.5 million public shares at $10.00 in May 2026, and every one of them can be redeemed for trust instead of staying in the deal. If they all are, and on the share counts in the presentation the rollover stake would rise toward 38% of a smaller pot, the company loses $75 million of cash while the original owners keep a larger slice.

Corxel is not being punished by the SPAC structure; it is being priced by a market that has already discounted oral GLP-1 assets. Structure Therapeutics held $1.34 billion of cash and short-term investments at June 30, 2026 and has burned roughly $224 million over the trailing twelve months, while its aleniglipron produced a placebo-adjusted 16.3% weight loss at 44 weeks in March 2026. A pre-revenue asset is being valued below the cash of a listed competitor that has already produced better-disclosed data.

The causal chain runs through the incumbents. Eli Lilly's Foundayo printed $98 million in the second quarter of 2026 against $1.2-1.6 billion of initial investor expectations and $1.5-2.8 billion of broker estimates for the year. A launch that misses by an order of magnitude reprices the class from scarcity to competition, and a pre-revenue Phase 3 asset priced into that reset has to win on data rather than on novelty. CX11's data is the weaker half of the comparison: 11.5% on an efficacy estimand against a placebo-adjusted 16.3% is not a like-for-like number, and the company has not published the placebo-adjusted figure.

Novo Nordisk sells obesity care into a market that grew 31% at constant currency to DKK 82,347 million in 2025 and still grew 22% at constant currency in the first quarter of 2026. The pill, launched in January 2026, booked DKK 2,256 million in that single quarter. Novo's pill locked up the first-mover slot months before CX11's Phase 3 even begins, and Corxel's own presentation concedes the crowding: it forecasts oral GLP-1 taking more than a third of the GLP-1 obesity market in a category running from $70 billion toward $160-170 billion, with semaglutide at $36.1 billion and tirzepatide at $36.5 billion in 2025.

The public vehicle is narrower than the company most investors have read about. Everest Medicines' two 2026 agreements with Corxel were signed with Corxel Pharmaceuticals Hong Kong Limited and Corxel Pharmaceuticals Limited — not with Corxel Pharmaceuticals, Inc., the entity going public. The listed company owns CX11 and CX12, while the group's China-facing assets were sold privately in 2026.

This is not a workaround for a closed IPO market; it is where the market has moved. Roughly two dozen biotech reverse mergers were announced by August 2026, more than double the ten recorded across all of 2025, and the average upfront cash and equity value of reverse mergers and SPACs fell to $398 million in the second quarter of 2026 from $1.5 billion in the first quarter. The SPAC route replaced the IPO window for biotech equity rather than merely adding to it — and the IPO window itself, in the first quarter of 2026, produced ten biotech deals for roughly $1.7 billion at a $287.5 million median.

The exit math explains why that matters. Metsera sold 15.3 million shares at $18.00 in January 2025 and was acquired by Pfizer eight months later at $47.50 a share in cash, roughly $4.9 billion at closing and up to $7.3 billion with contingent value rights. Strategic buyers pay up where the public market no longer does, and a listed SPAC vehicle is cheapest currency precisely for an asset strategic buyers have already passed on.

Short term, everything is mechanical: the shareholder vote, effectiveness of the registration statement, the Nasdaq listing approval and the redemption rate. Long term, the question is whether an oral small-molecule GLP-1 can still earn a place in a market where two pills were launched within four months. The next two quarters settle whether the money arrives; the next three years settle what it was worth.

Strip the structure away and this is a price-discovery event rather than a financing event. The market will still fund a de-risked obesity trial quickly and at scale — $377 million of gross proceeds, a syndicate of specialists, a runway to 2029 — but the price it pays no longer compensates for the risk taken to get there. Cost of capital is no longer the binding constraint on obesity assets; asset price is.